Currently, the BRAF inhibitors (BRAFis) approved by the Food and Drug Administration mainly include sorafenib, regorafenib, vemurafenib, dabrafenib, and encorafenib [1]; the last three are mainly used to treat patients with advanced melanoma, which also harbors a high BRAF mutation rate, and among them, vemurafenib, a BRAFV600E-specific small-molecule inhibitor, has significantly changed therapeutic prospects and been shown to quickly inhibit the growth of melanoma and control malignant tumor progression in most patients [2, 3]. Here, BRAF is linked to melanoma.